About Us

Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Our lead clinical candidate, KN-002, is a novel and non-invasive anti-inflammatory to treat all patients with severe asthma. With our founding investors, 5AM Ventures, Atlas Venture and Gimv, we are pursuing a patient-focused approach to build a leading respiratory therapeutics company.

Robert Clarke, PhD
Chief Executive Officer / Board Member / Co-Founder

Roger Heerman, MBA
Chief Business/Operating Officer / Co-Founder

Frazer Morgan
Chief Development Officer / Co-Founder

Julie Young, B.Pharm, PhD
Vice President of Clinical Operations

Jamil M. Beg, MBA
Independent Board Observer

Kevin Bitterman, Ph.D.
Partner, Atlas Venture

Tom King, MBA
Chair

Bram Vanparys, MBA, Ph.D.
Partner, Gimv

Robert Clarke, Ph.D.
CEO, Kinaset Therapeutics

Elliot Levy, M.D.
Venture Partner, 5AM Ventures

Ian Adcock, Ph.D.
Professor of Respiratory Cell & Molecular Biology, Imperial College

Gary Burgess M.B., ChB MMed(Int)(Stell) MFPM
Medical Consultant, GCB Clinical Consulting

Kristen Slaoui, Ph.D.
Chief Corporate Development Officer, Galderma

Dave Singh, M.D.
Professor, The University of Manchester